Use of the Probiotic Limosilactobacillus reuteri as an Adjunct to Subgingival Instrumentation in the Treatment of Periodontitis Patients With Diabetes: A Randomised Clinical Trial.
- 2025-09-17
- RCT · n = 40
- Journal of clinical periodontology 53(1)
- Rocío Bujaldón
- Eduardo Montero
- Juan Daniel Gamonal
- Alejandro Abuelo
- María José Marín
- Margarita Iniesta
- Mariano Sanz
- David Herrera
- PubMed: 40958659
- DOI: 10.1111/jcpe.70035
- High evidence
- Clinical
Both groups exhibited reductions in HbA1c levels after 6 months, more in the probiotic group (-0.6% vs. -0.1%), with statistically significant inter-group differences (-0.5%; 95% confidence interval [-1.0; 0.0]; p < 0.001).
- Effect
- Beneficial
- Effect size
- Moderate
- Significant
- Yes
- Dose
- tablets containing L. reuteri for 3 months (exact dose not specified in abstract)